AGAndrea Gingelmaier

Andrea Gingelmaier

*This is an algorithmically generated author record based on publicly available information.

Andrea Gingelmaier has a total of 57 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Influence of maternal age, gestational age and fetal gender on expression of immune mediators in amniotic fluid

    by Tobias Weissenbacher, Rüdiger P Laubender, Steven S Witkin, Andrea Gingelmaier, Barbara Schiessl, Franziskus Kainer, Klaus Friese, Udo Jeschke, Darius Dian, Katrin Karl

    Variations in cytokine and immune mediator expression patterns in amniotic fluid due to gestational age, maternal age and fetal gender were investigated. Amniotic fluid samples were obtained from 192 women, 82 with a mid-trimester amniocentesis (median gestational age 17 weeks) and 110 with a caesarean section not in labor (median gestational age 39 weeks). Amniotic fluid was screened by commercial ELISAs for the TH1/TH2/TH17 cytokines and immune mediators IL-1 beta, IL-2, IL-4, IL-6, IL-8, IL-10, IL-12, IL-15, IL-17, TNF alpha, GRO-alpha, MIP1alpha, MIP1beta, Histone, and IP10. Analysis was by Bonferroni correction for multiple comparisons. None of the 15 examined cytokines revealed any differences in expression patterns regarding fetal gender. Significant differences were found in IL-4, IL-10, IL-12, TNF- alpha, GRO-alpha and MIP1-beta with respect to gestational age and in GRO-alpha regarding maternal age. Cytokines utilized as biomarkers in the diagnosis of intrauterine infections are not influenced in their expression pattern by fetal gender but may vary with respect to maternal age and gestational age.


  • HIV infection during pregnancy

    by A. Gingelmaier

  • Consultations of HIV-infected women who wish to become pregnant

    by Andrea Gingelmaier, Katja Wiedenmann, Milena Sovric, Marianne Mueller, Markus S. Kupka, Ulrike Sonnenberg-Schwan, Ioannis Mylonas, Klaus Friese, Katharina Weizsaecker


    • 1 May 2010
      • Vol. 30  (5) , 1719-23

    Anal cytology as a screening tool for early detection of anal dysplasia in HIV-infected women.

    by Andrea Gingelmaier, Tobias Weissenbacher, Bernd Kost, Ralph Kaestner, Milena Sovric, Ioannis Mylonas, Klaus Friese, Florian Bergauer

    HIV-infected patients show a high rate of anal dysplasia and anal carcinoma but there is no gold standard for early detection. Therefore, the objectives of this prospective study were: a) evaluation of an anal screening using anal/perianal cytology; b) in case of a positive result to investigate its relation to immune status, clinical symptoms of HIV infection and antiretroviral therapy. In every HIV-infected woman visiting our gynaecological outpatient clinic, an anal and perianal swab for anal cytology was taken. One experienced cytologist examined all specimens. Relevant details of the HIV-related history such as CDC classification, CD4 count, viral load, actual antiretroviral therapy etc. were documented. Altogether, 104 HIV-infected women were enrolled on this study. The results of 13 (13.5%) anal cytologies were classified as suspicious for low-grade or high-grade anal dysplasia and 6 of these were confirmed in an anal biopsy. A total of 9 out of 13 also had a cervical dysplasia and 12 were positive for high-risk HPV at the cervix. Ten of these women had already experienced clinical symptoms of their HIV infection and 8 showed a nadir of the CD4 count below 200 cells/microl. All but one took a highly active antiretroviral therapy. In this pilot study, anal screening using anal cytology showed 13.5% suspected anal dysplasia in HIV-infected women. All performed biopsies revealed the presence of a high-grade anal lesion. The majority of these women already had an advanced disease and/or immune defect related to their HIV infection. In summary, we found anal cytology to be a useful tool to early detect anal dysplasia of high-risk patients such as HIV-infected women. How far this screening method contributes to the prevention of anal cancer has to be evaluated in further investigations.


  • Open Access

    Protease Inhibitor–Based Antiretroviral Prophylaxis during Pregnancy and the Development of Drug Resistance

    by Andrea Gingelmaier, Josef Eberle, Bernd P. Kost, Johannes R. Bogner, Joerg Hofmann, Tobias Weissenbacher, Ralph Kästner, Klaus Friese, Katharina Weizsaecker

    Background. The aim of this study was to determine the development of drug resistance among pregnant women receiving a protease inhibitor–based antir


  • Open Access

    The mitochondria-independent cytotoxic effect of nelfinavir on leukemia cells can be enhanced by sorafenib-mediated mcl-1 downregulation and mitochondrial membrane destabilization

    by Ansgar Brüning, Martina Rahmeh, Andrea Gingelmaier, Klaus Friese

    Nelfinavir is an HIV protease inhibitor that has been used for a long period of time to treat HIV-infected individuals. It has recently emerged that nelfinavir could represent a prospective new anti-cancer drug, prompting us to test the effect of nelfinavir on leukemia cells.


    • 28 April 2008
      • p. 44-5, 47

    [Maternofetal transmission of HIV].

    by Andrea Gingelmaier, Klaus Friese

  • Mitochondrial toxicity in HIV type-1-exposed pregnancies in the era of highly active antiretroviral therapy

    by Andrea Gingelmaier, Thomas A Grubert, Bernd P Kost, Bernhard Setzer, Dirk Lebrecht, Ioannis Mylonas, Josef Mueller-Hoecker, Udo Jeschke, Stephan Hiedl, Klaus Friese, et al.

    Background: The aim of this study was to determine the effects of HIV type-1 (HIV-1) infection and antiretroviral therapy (ART) on placental mitochondria. Methods: HIV-1-infected pregnant women and HIV-1 -uninfected controls were enrolled prospectively. Placental mitochondrial DNA (mtDNA) copy numbers were determined by quantitative PCR, subunits II and IV of cytochrome c oxidase (COX) were quantified by western blot and mitochondrial ultrastructure was evaluated by electron microscopy. Venous blood lactate was measured in newborns. Results: In total, 45 HIV-1-infected pregnant women on ART and 32 controls were included. Mean ±sd mtDNA copy numbers were significantly reduced in ART and HIV-1-exposed placentas (240 ±118 copies/ cell) in comparison with controls (686 ±842 copies/cell; P<0.001). The mean COX II/IV ratio was 48% lower in the investigational group compared with controls ( P<0.001). There was no evidence of severe ultrastructural damage within mitochondria of HIV-1-infected ART-exposed placentas. Although lactate levels between newborns did not differ, they were negatively correlated with placental mtDNA levels. There was no clear association between mitochondrial parameters and a particular nucleoside reverse transcriptase inhibitor (NRTI), the number of NRTIs or time of NRTI exposure. Conclusions: Placental tissue of HIV-1-infected ART-exposed pregnancies shows evidence of mtDNA depletion with secondary respiratory chain compromise. The clinical effects of this finding warrant further investigation.


    • 26 July 2007
      • Vol. 27, 1795-8

    High recurrence rate of cervical dysplasia and persistence of HPV infection in HIV-1-infected women.

    by Andrea Gingelmaier, Thomas Grubert, Ralph Kaestner, Ioannis Mylonas, Tobias Weissenbacher, Florian Bergauer, Lisa Barthell, Klaus Friese

    A) evaluation of the recurrence of cervical dysplasia after surgical treatment and of the rate of HPV persistence of HIV-infected women and b) the influence of antiretroviral therapy on the recurrence. In a retrospective analysis, the follow-up data of HIV-positive women visiting our outpatient clinic regarding results of cervical cytology, cervical HPV detection, cervical biopsy, patient history of dysplasia and antiretroviral therapy were assessed. A total of 388 HIV-positive women had a mean follow-up of 2.7 years and a median of 2.5 outpatient visits. Out of the 344 patients (57.3%) tested for HPV, 197 showed at least one positive HPV result. Of the same group, 136 women had four or more HPV tests which showed that 84 of them (61.8%) had a persistent HPV-infection. Overall, 157/388 had cervical dysplasia and 70 needed surgery. Forty-one of the 70 patients (58.6%) received more than one surgical treatment because of a recurrence, all of this group had persistent HPV. The recurrence of cervical dysplasia in HIV-positive women after surgical treatment was found to be very high as was the associated long-term persistence of HPV-infection. HPV persistence represented an excellent marker for relapsing cervical dysplasia.


    • 26 July 2007
      • Vol. 27, 2005-10

    The immunohistochemical expression of the inhibin/activin subunits is up-regulated by interferon-beta1a in Ishikawa cell line.

    by Anna Hoeing, Christina Kuhn, Naim Shabani, Sandra Schulze, Andrea Gingelmaier, Darius Dian, Udo Jeschke, Klaus Friese, Ioannis Mylonas

    Inhibins are dimeric glycoproteins belonging to the TGF-beta1 family and are composed of an a-subunit (INH-alpha) and one of two possible beta-subunits (betaA or betaB; INH-betaA and INH-betaB). They have a substantial function in human reproduction and also seem to play an important role in endocrine-responsive tumors. Interestingly, there is an association between interferon and TGF-beta expression. However, this relationship has not been assessed in endometrial tissue regarding inhibin/activin expression. Therefore, the aim of this study was to determine expression changes of inhibin/activin subunits in the endometrial Ishikawa carcinoma cell line after stimulation with interferon-beta1a. The Ishikawa cell line was cultured until confluence was observed (after 2 days). After adding interferon-beta1a (1000 IE/ml) Ishikawa cells were immunohistochemical analyzed for INH-alpha, INH-betaA and INH-betaB subunits. Experiments were performed in triplicates. The immunohistochemical expression was analyzed with a semiquantitative score (IRS) and statistical analysis was performed. Immunohistochemical reaction with INH-alpha could not be demonstrated in unstimulated cells, while it was significantly up-regulated in interferon-stimulated cells (p < 0.02). INH-betaA and INH-betaB were primarily observed during the mitotic phases of unstimulated cells. After stimulation their expression was significantly higher (p < 0.05 each) compared to controls and could be observed not only during mitotic phases but also in nonmitotic cells. For the first time, we demonstrated a functional relationship between interferon and inhibin/activin subunits. The expression of INH-alpha, INH-betaA and INH-betaB were immunohistochemical significantly up-regulated in the Ishikawa endometrial cell line after stimulation with interferon-beta1a. Since INH-alpha is thought to be tumor suppressive in the mouse model, interferon-beta1a might activate its gene. It remains to be clarified if this effect can be used as therapeutic options in endometrial carcinomas.